Joseph Shulman
Known title: Chief Technical OfficerCIK: 0001909855
Associated companies
Transaction History
| RYTM | ▲ Buy | Option Exercise | 2,024 | $14K | 8/13/2026 | View on chart |
| RYTM | ▼ Sell | Open Market | 5,079 | $608K | 8/13/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 16,968 | — | 2/1/2026 | View on chart |
| RYTM | ▼ Sell | Tax Withholding | 6,507 | $709K | 2/1/2026 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 9,748 | $299K | 10/30/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 9,748 | $1.1M | 10/30/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,094 | $57K | 10/28/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 721 | $22K | 10/28/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 2,815 | $324K | 10/28/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,093 | $57K | 10/16/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 12,344 | $378K | 10/16/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 3,412 | $385K | 10/16/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 8,332 | $934K | 10/16/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 2,693 | $299K | 10/16/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,094 | $57K | 9/2/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 14,687 | $450K | 9/2/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 16,781 | $1.8M | 9/2/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 4,188 | $419K | 8/21/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 4,188 | $115K | 8/21/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 3,984 | $359K | 8/11/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 3,984 | $27K | 8/11/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 3,984 | $301K | 7/9/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 3,985 | $319K | 7/9/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 7,969 | $54K | 7/9/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,228 | $70K | 2/19/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 4,125 | — | 2/16/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 7 | $400 | 2/12/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 462 | $26K | 2/12/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,562 | — | 2/11/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 3 | $173 | 2/11/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 791 | $45K | 2/11/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,656 | — | 2/9/2025 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,281 | $76K | 2/4/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 3,938 | — | 2/1/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 5,312 | $114K | 11/11/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 5,977 | $401K | 11/11/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 6,604 | $434K | 11/11/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 700 | $47K | 11/11/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 7,969 | $54K | 11/11/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 10,468 | $286K | 7/16/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 10,468 | $555K | 7/16/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 5,313 | $266K | 7/12/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 5,313 | $114K | 7/12/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 3,984 | $27K | 5/9/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 3,484 | $134K | 5/9/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 500 | $20K | 5/9/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 18,235 | $736K | 3/21/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 15,515 | $608K | 3/19/2024 | View on chart |
| RYTM | ▲ Buy | Grant | 33,750 | $0 | 2/16/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,089 | $54K | 2/14/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,865 | $93K | 2/13/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 473 | $24K | 2/13/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 791 | $41K | 2/12/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,562 | — | 2/11/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,656 | — | 2/9/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 69,190 | $1.5M | 2/9/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 48,177 | $2.4M | 2/9/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 23,397 | $1.2M | 2/9/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 100 | $5K | 2/9/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 100 | $5K | 2/9/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 3,938 | — | 2/1/2024 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,324 | $60K | 2/1/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 6,800 | $145K | 12/28/2023 | View on chart |
| RYTM | ▼ Sell | Open Market | 7,926 | $396K | 12/28/2023 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,400 | $51K | 12/27/2023 | View on chart |
| RYTM | ▼ Sell | Open Market | 5,015 | $251K | 12/27/2023 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 27,890 | $190K | 11/14/2023 | View on chart |
| RYTM | ▼ Sell | Open Market | 27,890 | $894K | 11/14/2023 | View on chart |
| RYTM | ▼ Sell | Open Market | 554 | $15K | 2/14/2023 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,563 | — | 2/11/2023 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,657 | — | 2/9/2023 | View on chart |
| RYTM | ▼ Sell | Open Market | 921 | $25K | 2/9/2023 | View on chart |
| RYTM | ▼ Sell | Open Market | 557 | $3K | 2/15/2022 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 1,563 | — | 2/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RYTM: RBC raises price target to $159, maintains Outperform
RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.
RYTM: RBC raises price target to $159, maintains Outperform. RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.